Diabetes and chronic kidney disease: Prevention, early recognition, and treatment

Consultant

Volumn 54, Issue 1, 2014, Pages

  Shahady, Edward ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; EZETIMIBE; GLIBENCLAMIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINAGLIPTIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA;

ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; EARLY INTERVENTION; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HUMAN; MEDICAL DECISION MAKING; MEDICARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; SCREENING; URINARY EXCRETION;

EID: 84893130991     PISSN: 00107069     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. United States Renal Data System. Annual Data Report 2012. Introduction. Available at: www.usrds.org/2012/pdf/v2-00intro-12.pdf. Accessed November 15, 2013.
2. United States Renal Data System. Annual Data Report 2012. Chapter 1. Incidence, prevalence, patient characteristics and mortality. http://www.usrds.org/2012/view/v2-01.aspx. Accessed November 13, 2013.
3. Kidney statistics for the US. National Kidney and Urologic Disease Clearinghouse. Available at: http://kidney.niddk.nih.gov/kudiseases/pubs/ kustats/KU-Diseases-Stats-50. Accessed November 15, 2013.
4. Honeycutt AA, Segel JE, Zhuo X, et al. Medical costs of CKD in the medicare population. J Am Soc Nephrol. 2013;24:1478-1483.
5. Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012;307:1941-1951.
6. Fink HA, Ishani A, Taylor BC, et al. Chronic kidney disease stages 1-3: screening, monitoring, and treatment. Comparative Ef fectiveness Review No. 37. AHRQ Publication No. 11(12)-EHC075-EF. Agency for Healthcare Research and Quality. 2012 Jan. Available at: www.effectivehealthcare.ahrq.gov/ehc/products/ 163/809/CER37-ChronicKidne. Accessed November 15, 2013.
7. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diab etes Care. 2004;27(suppl 1):S79-S83.
8. Standards of medical care in diabetes-2013. Diab etes Care. 2013;36(suppl 1):S11-S66.
9. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter Suppl. 2013;3:1-150.
10. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
12. Skyler JS. Diabetic complications. The importance of glucose control. Endocrinol Metab Clin North Am. 1996;25:243-254.
13. Ferrannini E, Buzzigoli G, Bonadona R. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-357.
14. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
15. Patel A, MacMahon S, Chaimer J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-840.
16. Van Buren PN, Toto RD. The pathogenesis and management of hypertension in diabetic kidney disease. Med Clin North Am. 2013;97:31-51.
17. Wang Y, Shu KH, Yang MF, et al. The impact of body weight management in chronic kidney disease patients with obesity. J Ren Nutr. 2013;23:372-379.
18. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo controlled trial. Lancet. 2011;377(9784):2181-2192.
19. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361(9374):2005-2016.
20. Ix JH. Hemoglobin A1c in hemodialysis patients: should one size fit all? Clin J Am Soc Nephrol. 2010;5:1539-1541.
21. Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis. 2004;44:715-719.
22. Alskär O, Korell J, Duffull SB. A pharmacokinetic model for the glycation of albumin. J Pharmacokinet Pharmacodyn. 2012;39:273-282.
23. Abe M, Matsumoto K. Glycated hemoglobin or glycated albumin for assessment of glycemic control in hemodialysis patients with diabetes? Nat Clin Pract Nephrol. 2008;4:482-483.
24. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-To-moderate renal insufficiency. Diab etes Care. 2011;34:1431-1437.
25. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49;(2 suppl 2):S12-S154.
26. Sarafidis PA, Stafylas PC, Georgianos PI, et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-Analysis. Am J Kidney Dis. 2010;55:835-847.
27. Schneider CA, Ferrannini E, Defronzo R, et al. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol. 2008;19:182-187.
28. Habib ZA, Havstad SL, Wells K, et al. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95:592-600.
29. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diab etes Ob es Metab. 2011;13:939-946.
30. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc; 2011.
31. Bydureon [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2013.
32. Victoza [package insert]. Princeton, NJ: Novo Nordisk Inc; 2013.
33. Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial. 2000;13:4-8.
34. Baldwin D, Zander J, Munoz C, et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diab etes Care. 2012;35:1970-1974.